Cyclo Therapeutics Future Growth

Future criteria checks 2/6

Cyclo Therapeutics is forecast to grow earnings and revenue by 54.2% and 60.3% per annum respectively while EPS is expected to grow by 57.3% per annum.

Key information

54.2%

Earnings growth rate

57.3%

EPS growth rate

Biotechs earnings growth	27.3%
Revenue growth rate	60.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	27 Aug 2024

Recent future growth updates

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Earnings and Revenue Growth Forecasts

NasdaqCM:CYTH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	33	-10	N/A	N/A	2
12/31/2026	15	-22	N/A	N/A	2
12/31/2025	1	-27	N/A	-24	3
12/31/2024	1	-22	N/A	-22	3
9/30/2024	1	-25	-23	-23	N/A
6/30/2024	1	-21	-18	-18	N/A
3/31/2024	1	-19	-18	-18	N/A
12/31/2023	1	-20	-16	-16	N/A
9/30/2023	1	-19	-15	-15	N/A
6/30/2023	1	-19	-14	-14	N/A
3/31/2023	1	-18	-15	-15	N/A
12/31/2022	1	-15	-15	-15	N/A
9/30/2022	2	-13	-15	-15	N/A
6/30/2022	2	-13	-15	-15	N/A
3/31/2022	1	-13	-15	-15	N/A
12/31/2021	2	-14	-15	-15	N/A
9/30/2021	1	-14	-15	-15	N/A
6/30/2021	1	-12	-14	-14	N/A
3/31/2021	1	-10	-12	-12	N/A
12/31/2020	1	-9	-9	-9	N/A
9/30/2020	1	-9	-8	-8	N/A
6/30/2020	1	-9	-8	-8	N/A
3/31/2020	1	-8	-7	-7	N/A
12/31/2019	1	-8	-7	-7	N/A
9/30/2019	1	-6	-5	-5	N/A
6/30/2019	1	-5	-4	-4	N/A
3/31/2019	1	-5	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-4	-3	-3	N/A
6/30/2018	1	-4	N/A	-3	N/A
3/31/2018	1	-4	N/A	-3	N/A
12/31/2017	1	-4	N/A	-3	N/A
9/30/2017	2	-3	N/A	-3	N/A
6/30/2017	2	-4	N/A	-3	N/A
3/31/2017	1	-5	N/A	-3	N/A
12/31/2016	2	-4	N/A	-3	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-4	N/A	-3	N/A
3/31/2016	1	-3	N/A	-2	N/A
12/31/2015	1	-3	N/A	-2	N/A
9/30/2015	1	-2	N/A	-1	N/A
6/30/2015	1	-1	N/A	-1	N/A
3/31/2015	1	-1	N/A	-1	N/A
12/31/2014	2	-1	N/A	-1	N/A
9/30/2014	1	0	N/A	0	N/A
6/30/2014	1	0	N/A	0	N/A
3/31/2014	2	0	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYTH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYTH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYTH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYTH's revenue (60.3% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: CYTH's revenue (60.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CYTH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/03 03:39
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyclo Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lucas Ward	Ascendiant Capital Markets LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group

Cyclo Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 12%

Consensus revenue estimates decrease by 29%, EPS upgraded

Consensus forecasts updated

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Consensus forecasts updated

Recent updates

Cyclo Therapeutics Receives Non-Compliance Letter from Nasdaq Stock Market

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update

First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020)

Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Independent Chairman recently bought US$81k worth of stock

Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019)

Earnings and Revenue Growth Forecasts